TAKEDA PHARMACEUTICALS AMERICA, INC.

View full entity profile (contributions, contracts, SEC) →

Lobbying Spend

—

Filings

Firms Hired

Active Period

2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	—	3	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
AVENUE SOLUTIONS	—	3

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	1
SENATE	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	3

Bills Explicitly Cited (1)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 4299119th Congress

Protecting Patient Access to Cancer and Complex Therapies Act

2026 · third_quarter · Firm: AVENUE SOLUTIONS

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing and reimbursement for prescription drugs; Issues related to H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act

Client expense: — · Firm income: $50,000

Matched citations: H.R. 4299

Source: Senate LDA

TAKEDA PHARMACEUTICALS AMERICA, INC. — Lobbying Disclosure | Poliscope